Chong Kun Dang is conducting a clinical trial to develop a triple combination therapy, aiming to strengthen its competitiveness in the diabetes treatment market.

On June 12th, the Ministry of Food and Drug Safety (MFDS) approved Chong Kun Dang’s application for a phase 1 trial for the “Evaluation of the Impact of Dietary Intake on Pharmacokinetic Profiles and Safety of CKD-383 in healthy adults.”

CKD-383 is a triple combination therapy with CKD’s 'Duvie (lobeglitazone),' Boehringer Ingelheim Korea's 'Jardiance (empagliflozin),' and 'metformin,' which is used for the first-line treatment of type 2 diabetes.

Chong Kun Dang has been conducting a phase 1 trial